Key result
The current IPV schedule with the first dose at 6 months resulted in the highest persisting antibody titers against PV1 and PV2 at 3 years of age compared to earlier onset schedules.
Why the study?
Do different three-dose schedules of inactivated poliovirus vaccine affect antibody responses in children?
Do different three-dose schedules of inactivated poliovirus vaccine affect antibody responses in children?
Answers are grounded in this paper and cite their sources.
Three doses of IPV provide satisfactory immune responses, but very early onset and short dosage intervals should be avoided for optimal persisting antibody levels.
Antibody responses were studied in five groups of children immunized with different three-dose schedules of inactivated poliovirus vaccine (IPV). The age of the child at the first dose (1-4 months) and the interval between the first and second doses (2-4 months) influenced the initial responses in a serotype-dependent manner. All the groups attained sufficient antibody level after three doses but the third dose given at 18 months resulted in higher persisting antibody levels than that given at 12 months. The highest persisting antibody titers against PV1 and PV2 (but not against PV3) at the age of 3 years were measured in the control group immunized with the current schedule (P < 0.001) in which the first dose is given at 6 months. The level of maternal antibodies present at the time of the first dose correlated negatively with the antibody titers as late as at 3 years of age. It is concluded that three doses of IPV given in widely variable schedules may result in satisfactory immune responses in children but, for optimal results, very early onset of the program and short dosage intervals should be avoided.
No takes yet. Share an insight, caveat, or question.
Sormunen et al. (2001) studied Polio immunization. Inactivated poliovirus vaccine (IPV) in early onset schedules vs. Current schedule (first dose at 6 months) was evaluated on Persisting antibody titers against PV1, PV2, and PV3 at 3 years of age (p=<0.001). The current IPV schedule with the first dose at 6 months resulted in the highest persisting antibody titers against PV1 and PV2 at 3 years of age compared to earlier onset schedules.
Synapse has enriched 10 related papers. Consider them for comparative context: